(DIAGNOSTIC IMAGING) -- FDA Approves DaTscan to Assist in Evaluation of Neurodegenerative Movement Disorders
By Sara Michael
GE Healthcare announced recently that the FDA has approved the first imaging agent to help physicians in evaluating neurodegenerative movement disorders.
The FDA approved ioflupane I 123 injection (DaTscan), a radiopharmaceutical agent intended for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters in the brains of adult patients with suspected parkinsonian syndromes.
See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC